- Home
- PBYI vs HBIO Comparison
PBYI vs HBIO Comparison
Compare PBYI & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- HBIO
- Stock Information
- Founded
- PBYI 2010
- HBIO 1901
- Country
- PBYI United States
- HBIO United States
- Employees
- PBYI N/A
- HBIO N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- PBYI Health Care
- HBIO Industrials
- Exchange
- PBYI Nasdaq
- HBIO Nasdaq
- Market Cap
- PBYI 164.3M
- HBIO 19.6M
- IPO Year
- PBYI N/A
- HBIO 2000
- Fundamental
- Price
- PBYI $3.56
- HBIO $0.45
- Analyst Decision
- PBYI Strong Buy
- HBIO Buy
- Analyst Count
- PBYI 1
- HBIO 2
- Target Price
- PBYI $7.00
- HBIO $3.00
- AVG Volume (30 Days)
- PBYI 299.1K
- HBIO 2.1M
- Earning Date
- PBYI 07-31-2025
- HBIO 08-07-2025
- Dividend Yield
- PBYI N/A
- HBIO N/A
- EPS Growth
- PBYI 143.51
- HBIO N/A
- EPS
- PBYI 0.77
- HBIO N/A
- Revenue
- PBYI $232,709,000.00
- HBIO $91,397,000.00
- Revenue This Year
- PBYI N/A
- HBIO N/A
- Revenue Next Year
- PBYI N/A
- HBIO $9.75
- P/E Ratio
- PBYI $4.64
- HBIO N/A
- Revenue Growth
- PBYI 2.68
- HBIO N/A
- 52 Week Low
- PBYI $2.23
- HBIO $0.28
- 52 Week High
- PBYI $4.13
- HBIO $3.60
- Technical
- Relative Strength Index (RSI)
- PBYI 56.71
- HBIO 47.38
- Support Level
- PBYI $3.49
- HBIO $0.42
- Resistance Level
- PBYI $3.65
- HBIO $0.48
- Average True Range (ATR)
- PBYI 0.13
- HBIO 0.05
- MACD
- PBYI 0.01
- HBIO -0.01
- Stochastic Oscillator
- PBYI 75.80
- HBIO 15.75
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.